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Take Note --------.......---1
Colon cancer screening
saves lives and gives peace
of mind.
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Creating realistic expecta~
tions of sexual function
after prostate cancer.
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Researchers
Focus on
Improving
Therapies and
Identifying
Biomarkers
by Katie Prout Matias
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truth, it is one of the
most common cancers
in the United States, has a high
rate of recurrence, and kills
more than 12,000 people each
year. But the disease has devel~
oped a reputation for being
Researchers from the Department of Urology-including Dr. H. Barton Grossman
(foreground), a professor; Dr. Noriyoshi Tanaka (left), a postdoctoral fellow ; Jorge
nonlethal. This misperception,
Delacerda , supervising clinical researcher; and Afsaneh Keyhani (right), laboratory
according to Colin P.N.
coordinator-are investigating new treatment approaches for bladder cancer.
Dinney, M. D. , a professor in
blame for the longtime dearth
the Department of Urology at
TI-E lNIVERSilY OF TEXAS
The University of Texas M. D. of funding for bladder cancer
Anderson Cancer Center, is to
research. (Continued on next page)

MDANJERSON

CANCER CENTER

'Hitting Bladder Cancer on All Fronts'
(Continued from page 1)

In recent years, however, the National Cancer Institute (NCI) has taken
steps to reverse this trend. NCI funding
for bladder cancer research increased
from $15.5 million in 1997 to $32.3
million in 2002. And in 2001, the NCI
awarded a $13.9 million Specialized
Program for Research Excellence
(SPORE) grant for bladder cancer
research to M. D. Anderson. Within
the program, five core research projects
will study everything from prevention
to detection and treatment. "We're
hitting bladder cancer on all fronts,"
said Dr. Dinney, who directs the bladder
cancer SPORE.
One of the chief goals of researchers
at M. D. Anderson is to improve on the
current standards of care for superficial
and muscle-invasive bladder cancer,
which are far from perfect. Patients
with superficial bladder cancer are often
treated with transurethral resection and,
in some cases, intravesical chemotherapy.
N evertheless, 50% to 75% of superficial
bladder cancers recur, and these recurrent tumors are treated with bacille
Calmette-Guerin (BCG), an attenuated
tuberculosis bacterium that is used as
immunotherapy. In this treatment, a
saline solution containing the bacteria
is deposited into the bladder via a
catheter, where it triggers the body's
immune response, destroying cancer
cells. BCG is used more or less as a
maintenance therapy, to delay the next
recurrence that is likely to come.
"Even though we have effective
therapies for the treatment of superficial
disease, most bladder cancers over time
will recur," said Dr. Dinney. "And the
salvage therapies that we have today
are not very effective." Up to 30% of
patients in whom superficial bladder
cancer recurs will die within 15 years.
Approximately 25% of bladder
cancers will invade the muscle, requiring a cystectomy, or total removal of
the bladder. Cystectomy can have
many troubling side effects, including
impotence resulting from nerve damage
and urinary incontinence. The prostate,
ovaries, uterus, and part of the vagina
are also commonly removed. Sadly, in
many of the patients who choose to go
2
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through a cystectomy, the cancer will
recur. "Up to 50% of patients who
present with muscle-invasive disease
will die of metastasis, as will a small
percentage of patients who have
superficial disease. So there is a real
need to develop better therapies," said
Dr. Dinney.
Researchers are investigating many
different treatment approaches, including better chemotherapeutic strategies
for metastatic, chemotherapy-resistant
bladder cancer. One such strategy, still

Superficial Bladder Cancer

Invasive Bladder Cancer

Superficial bladder cancers (top) are
often treated with transurethral resection;
immunotherapy is used in the 50% to
75% of superficial bladder cancers that
recur. Approximately 25% of bladder
cancers invade the muscle, requiring
a cystectomy, or total removal of the
bladder. Researchers at M. D. Anderson
are studying better ways to prevent
recurrence and treat patients with both
kinds of bladder cancer.

considered controversial by many, is
neoadjuvant chemotherapy before
cystectomy. According to Dr. Dinney,
neoadj uvant chemotherapy not only is
the first step toward bladder preservation
but also allows physicians to observe
whether the chemotherapy is working.
"If you take out the bladder and then
give them chemotherapy after the fact,
you really don't know if that chemotherapy has been effective because
there's nothing to watch. If you leave
the bladder tumor inside, you can
actually evaluate it during the course
of chemotherapy and determine how
effective the therapy is," said Dr.
Dinney. "And if it's not effective, you
can change the course of treatment
in the midst of it and not wait to see
the can cer recur at the end of it all."
In patients with locally advanced
bladder cancer, the survival benefit of
neoadjuvant chemotherapy was recently
confirmed by an 11-year study of 307
patients conducted by the Southwest
Oncology G roup and led by H. Barton
Grossman, M.D., a professor in the
Department of u;ology at M. D.
Anderson . The study's results, which
were published in the August 28, 2003,
issue of The New England Journal of
Medicine, showed that patients treated
with chemotherapy fo llowed by surgery
lived a median of 77 months, compared
with 46 months for patients treated
with surgery alone.
"This is an important advance,
because the study shows a significant
and clinically meaningful improvement
in survival among patients who received
chemotherapy before surgery," said Dr.
Grossman. "Treatment of this disease
varies across the country, but we believe
neoadjuvant chemotherapy should be
used more frequently."
Also being investigated to improve
chemotherapeutic treatments is interferon, which has so far not been successful alone in treating muscle-invasive
bladder cancer. In one study, patients
will receive interferon systemically, and
biopsies will be performed before and
after treatment to see if the interferon is
indeed killing cancer cells and enhancing the response to the chemotherapy.

"Up to 50% of patients who
present with muscle-invasive
disease will die of metastasis,
as will a small percentage
of patients who have
superficial disease. So there
is a real need to develop
better therapies."
- Colin P.N. Dinney, M.D., professor,
Department of Urology

In patients for whom the treatment
does not work, the researchers will study
the biological mechanisms behind the
resistance and use the results to select
patients for interferon treatment.
Another agent being combined
with chemotherapy is ZD- 1839 (Iressa),
an epidermal growth factor receptor
(EGFR)-blocking agent. EGFR, which
is overexpressed in more than 80% of
advanced bladder cancers, is involved
in many important aspects of tumor cell
growth and invasion, including angiogenesis. Patients whose disease responds
to chemotherapy will receive ZD-1839
in the hope that it will increase the
efficacy of the treatment.
The bladder has long been thought
to be ideal for gene therapy, but past
trials using adenoviral p53 did not
deliver enough of the gene to the tumor
cells. As part of an ongoing investigation, researchers will be delivering the
interferon-a gene, combined with a
compound called Syn3, intravesically in
patients with superficial bladder cancer.
"In our animal models, Syn3 has led to
tremendous gene transfer across the
bladder and caused regressions of human
bladder cancers growing in mice when
given intravesically," said Dr. Dinney.
In addition to looking for better
therapies, the researchers are working
to improve staging, detect recurrence
earlier, and develop effective chemoprevention regimens. According to Dr.
Grossman, who codirects the SPORE,
several projects are under way to find

genomic and proteomic biomarkers
that would help physicians diagnose
both primary and secondary bladder
cancer earlier. Currently, cystoscopy is
recommended every three to six months
to test for bladder cancer recurrence.
This invasive procedure can miss small
tumors and carcinoma in situ lesions,
however, and some patients do not
return for their scheduled follow-up.
If the biomarker studies are successful,
physicians could instead test a patient's
urine for certain genes or proteins,
saving them from the discomfort and
expense of a cystoscopy.
"Both the genomic and proteomic
approaches are yielding very exciting
information," said Dr. Grossman. "The
proteomic approach has identified a
series of protein peaks that appear to be
very sensitive and specific for detecting
bladder cancer."
Using genetic or proteomic markers
for bladder cancer, physicians also could
identify patients who would be good
candidates for novel therapies ( in place
of cystectomy), said Dr. Dinney, as
well as patients who are likely to have
recurrent or invasive cancer and whose
disease should be treated more aggressively sooner. "These markers may help
us identify those patients who actually
respond to the chemotherapy and have
a complete pathologic response, which
is very hard to determine clinically
before taking the bladder out. Your error
is probably 30%, and that can be a very
serious error," he said. Physicians could

also know if and when to perform a
cystectomy on someone with superficial
bladder cancer, thus resolving one of the
bigger controversies in urologic oncology.
Finally, biomarkers could also help
corroborate the efficacy of chemopreventi ve drugs. Two chemopreventive
agents currently being evaluated at
M. D. Anderson for bladder cancer
prevention are fenretinide and celecoxib, which is intended to prolong
the response to BCG. Both drugs are
being investigated to prevent or
delay recurrences.
"One of the problems with chemoprevention trials is that our ability to
determine response is still very limited,"
said Dr. Grossman. "If validated biomarkers were available that could be
used as surrogate endpoints, you could
assess chemoprevention in a much
faster, more efficient way."
The epidemiology of bladder cancer
recurrence is another area of investigation. Cigarette smoking and exposure
to certain chemicals are known causes
of bladder cancer initially, but it is not
clear what triggers recurrences. Variations in normal genes are being investigated, including those involved in
DNA repair, nicotine addiction, and
the ability to break down carcinogens
into nontoxic byproducts. Researchers
hope that the knowledge gained from
these studies could one day be used to
develop not only chemopreventive
drugs to prevent recurrence but also
primary prevention methods for people
at high risk of bladder cancer, such as
smokers, industrial workers, and those
who carry certain genetic markers.
The knowledge researchers gain in
their efforts to improve the prevention,
diagnosis, and treatment of bladder
cancer may also be applicable to other
solid tumors that are more difficult to
evaluate. "The bladder is an internal
organ that is very, very accessible, so
it provides a unique opportunity for
developing therapies," said Dr.
Grossman. •
FOR MORE INFORMATION, contact
Dr. Dinney or Dr. Grossman at

(713) 792-3250 .
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Restoring Erectile Function in Patients Treated l
Efforts across Disciplines Address Physical, Psychologi,cal, and Emotional Facto

1

by Mariann Crapanzano

he message for men
facing prostate
cancer and its treat-ment is clear: erectile
dysfunction, a major morbidity
associated with radical prostatec-tom y and radiation therapy, can
be effectively treated. At The
University of Texas M. D.
Anderson Cancer Center,
health--care professionals across
disciplines work with patients
to restore erectile function after
treatment for prostate cancer,
addressing the physiological,
psychological, and emotional
factors involved in penile erec-tion from the time of surgery
through rehabilitation. The
results are promising.

T

In the effort to maintain or restore
spontaneous erectile function in
patients after prostatectomy, surgeons
have devoted considerable attention to
the preservation of nerve function, a
fundamental component of tumescence.
------RailiC---al--pres-rateewm-y-i-r1:ve>-l-ves-remova-1------'-----,- - ~--~- ----,---of the prostate, surrounding lymph
nodes and tissue, and occasionally, the
surrounding cavernous nerve bundles
that play a central role in penile
erection. A nerve-sparing surgical
technique that has been widely used
since the 1980s for patients with
Nelda J. Huber (left), a physician's assistant in the Department of Urology, and Dr.
localized prostate cancer has helped
Run Wang , an assistant professor in the department and director of the erectile dysfuncto increase the number of men who
tion clinic, examine an inflatable penile prosthesis, one of several devices used in the clinic
recover potency-defined as the ability
to help men regain erectile function .
to sustain an erection sufficient for
sexual intercourse-after surgery.
age, the disease stage, and the degree
candidates for the nerve-sparing
The results with nerve-sparing
of erectile function before the surgery.
technique because of the risk of positive
surgery vary by patient, said Richard J.
Younger age, organ-confined disease,
surgical margins. For these patients, a
Babaian, M.D., a professor in the
and good preoperative function lead
surgical procedure in which the sural
Department of Urology at M. D.
to better results.
nerve from the leg is grafted to the
Anderson, but three factors that help
Some patients, such as those whose
cavernous nerve stumps provides
determine the outcome are the patient's cancer is locally advanced, may not be
promise. In a study reported in the
4
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for Prostate Cancer
rs Related to Sexual Potency
March 2003 issue of Plastic & Reconstructive Surgery, Dr. Babaian and his
colleagues at M. D. Anderson evaluated
the effectiveness of sural nerve grafting
of the cavernous nerve bundles in
preserving postoperative erectile
function while providing the highest
level of cancer control. The results were
encouraging. Among 30 patients who
underwent non-nerve-sparing prostatectomy and a bilateral sural nerve
graft, 18 (60%) had spontaneous
erectile activity during a mean followup period of 23 months after surgery.
Thirteen ( 72 % ) of these 18 men were
able to engage in sexual intercourse
either spontaneously or after taking
sildenafil.
According to Dr. Babaian, the
recovery period after the nerve graft is
necessarily longer than it is after nervesparing surgery because it takes time for
the nerve to grow. The sural nerve that
is grafted is not itself a live, functioning
nerve; instead, it acts as a scaffold upon
which the two ends of the cavernous
nerve will regenerate an d complete
the path to the innervated tissue.
This process takes 15 to 18 months.
Christopher G. Wood, M.D., a
surgeon and assistant professor in
the Department of Urology at M. D.
Anderson and a coinvestigator in the
bilateral sural nerve graft study, said that
some patients who are not candidates
for bilateral nerve-sparing surgery can
undergo unilateral nerve-sparing surgery.
According to Dr. Wood, biopsy results
determine whether the patient has highgrade or locally advanced disease that
would preclude sparing the nerve. Those
who require unilateral nerve resection
for cancer control are eligible for a phase
II, randomized trial that is currently
recruiting patients at M. D. Anderson to
determine the benefits of unilateral sural
nerve grafting. Potential participants are
patients 65 years of age or younger who
are candidates for unilateral nervesparing surgery and who have not
received pelvic radiation therapy or
hormone therapy for their prostate
cancer. Participants will be randomly
assigned to receive postoperative

"Patients should start this
rehabilitation as early as possible."
- Run Wang, M.D., assistant professor,
Department of Urology

erectile-function therapy only or
erectile-function therapy plus a unilateral nerve graft.
Preserving the nerves responsible
for tumescence is just one method of
recovering erectile function after
prostate cancer treatment. Rehabilitation is an integral part of this recovery,
regardless of the cancer treatment, and
at M. D. Anderson, programs are in
place to help patients not only physically but also psychologically and
emotionally.
Dr. Wood, who recognized years
ago that early erectile function rehabilitation is critical to the recovery
and maintenance of spontaneous
penile erections after treatment for
cancer, was instrumental in developing
the erectile dysfunction clinic in the
Department of Urology. Here, patients
with erectile dysfunction caused by
their cancer treatment undergo
therapy that includes one or more
of the following regimens: oral
sildenafil, penile injections, intraurethral suppositories, vacuum erectile
devices, and penile implants, all of
which help patients to achieve erections and thus exercise function
during recovery.

The success of this therapy is
explained physiologically, said Run
Wang, M.D., an assistant professor in
the Department of Urology and director
of the erectile dysfunction clinic at
M. D. Anderson. According to Dr.
Wang, the penile erections caused by
the therapy mimic the spontaneous
nocturnal tumescence that occurs in
healthy adult males; this increases blood
flow to the penis, helping to prevent
hypoxia and thus fibrosis, collagen
formation, and loss of tissue mass.
"Patients should start this rehabilitation as early as possible," said Dr. Wang,
who also serves as chief of urology at
Lyndon B. Johnson General Hospital
and assistant professor of surgery at
The University of Texas Health Science
Center at Houston Medical School.
"With nerve-sparing or non-nervesparing surgery, every patient should do
this to maintain the healthy tissues, to
facilitate early recovery of their erection, and to make it easier for them to
receive possible surgical help, such
as penile implants, in the future."
How successful is the therapy? It
depends on the patient and the regimen, said Dr. Wang. As an example,
(Continued on page 6)

Dr. Richard J. Babaian , a professor in the Department of Urology, found that sural
nerve grafting after the removal of the cavernous nerve bundles can preserve postoperative
erectile function while providing the highest level of cancer control.
OncoLog • October 2003
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Restoring Erectile Function after Prostate Cancer Treatment
(Continued from page 5)

he said, patients who undergo nonnerve- paring prostatectomy have a
0% to 5% rate of spontaneou erections
without therapy versus a rate of erection as high as 80% with the aid of
penile injections.
Patient may also receive p ychological support to guide them through the
restoration of sexual potency. Leslie R.
Schover, Ph.D., a professor in the
Department of Behavioral Science, is
developing intervention program to
addre the emotional and relation hip
i ue faced by men with erectile
dy function and help couple return
to full, ati fying sexual intimacy after
pro tate cancer. As recognized by both
Ors. Babaian and Schover, physiologic
function is but one aspect of recovery.
Dr. Schover's studies are de igned to
educate men and their partners about
their medical option and to give them
the tool to help overcome the inevitable hurdles they will face on the road
to recovery.
In one pilot study, men who had
undergone either radical pro tatectomy
or radiation therapy for localized prostate
cancer and who were not receiving
hormonal treatment for their cancer
participated with their wive or partners
in a four- e ion intervention program
with a counselor. Filling out que tionnaire before and after the coun eling,
the men and women reported on their
sexual function and activity. The sessions
focu ed on helping couple enhance
their communication about ex and their
exual enjoyment, advising them about
available medical treatment options for
erection problems, and teaching them to
troubleshoot in the event a particular
treatment plan is unsuccessful. The
preliminary results showed that couples
who participated in the program experienced improved sexual function and
sati faction by three months after
treatment and that a greater percentage
of the men were succes fully using a
medical treatment to re tore erectile
function.
Or. Schover and her colleagues were
encouraged by these po itive changes
but recognized some barrier to providing thi type of program: not all commu6
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Dr. Wang agreed.
"Erectile d functi n can be cur d '
aid Dr. Wang. "If the patient i motiated to get tr at d, we can h lp him,
there n d ubt. •
FoR MORE INFORMATION contact Dr.
Babaianat (71 3) 792-325 Dr. Wood at
(713) 792-325 Dr. angat (7 13) 5 7324 , Dr. choerat (7 13 ) 745-26 l
or elda Huber at (71 3) 792-641 .

PHYSICIANS : THIS PATI EN T INFORMATION
SHEET IS YOURS TO COPY AND PASS ON TO PATIENTS .

Note to Self:
Get Screened for Colon Cancer
his memo is for every-one who is putting
off colon cancer
screening. You may
have come across this article on
your own , or it may have been
given to you by someone who
cares about you . No matter
how it came to you , this could
be the most important informa-tion you will read for some time.
Colon cancer screen ing is a sensitive
issue, and most people would prefer
not to think or talk about it. However,
screening is especially important in
colon cancer because most colon cancers
develop from polyps that start out small
and harmless but grow slowly and change
into cancer. Colon cancer often has no
special symptoms in its early stage, and it

affects men and women in equal numbers. More than 100,000 people are
diagnosed with colon cancer in the
United States every year, and it is the
second leading cancer killer in the U .S.
So when should you get screened
for colon cancer? The type of screening
used and its schedule will vary depending on your risk fac tors. Talk to your
doctor if you've had symptoms of colon
cancer, such as consistent presence of
blood in your stool, changes in bowel
habits, unexplained we ight loss, or
tiredness; if you or a relative has had
cancer before; or if you h ave other
poss ible risk factors, including certain
bowel diseases, a history of tobacco
use, or a diet high in fat or cholesterol.
(But note: Three out of four people
who have colon cancer h ad no known
risk fac tors. ) Even if you don't have
an y other risk factors, turning 50 years
old is reason enough to get screened.

. - - - - - - - - - - - --- Note,,tlJ ~elf:

Screening Tests
for Colon Cancer
■

get screene.dfor
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- and
Fecal Occult Blood Test: Special cards are coated with a stool sample
returned to the physician or lab. This test examines a patient's solid waste (stool)
for occult (hidden) blood. Stud ies show that a fecal occult blood test performed
every 1 or 2 years in people between the ages of 50 and 80 years decreases the
number of deaths due to colon cancer.

■

Sigmoidoscopy: Sigmoidoscopy is an examination in which a doctor uses
a thin, flexible tube with a light to look inside the rectum and colon f~r polyps,
tumors, or abnormal areas. Studies suggest that fewer people may die of colon
cancer if they have regular screening by sigmoidoscopy after the age of 50 years.

■

Digital Rectal Examination: A digital rectal examination is perf~rmed ~uri~g
an office visit or prior to sig moidoscopy or colonoscopy. For this examination,
the doctor or nurse inserts a lubricated gloved finger into the rectum and feels
for lumps or abnormal areas. The evidence available does not suggest that digital
rectal examination is effective in decreasing mortality from colon cancer.

■

■

Barium Enema: Barium enema is a procedure in which a liquid containing barium
is put into the rectum and colon by way of the anus. Barium is a silver-white
metallic compound that helps to show the image of the lower gastrointestinal
tract on an x-ray. Barium enema may be effective in detecting large polyps.
Colonoscopy: Colonoscopy is an examination of the inside of the colon and rectum
using a thin , lighted tube (called a colonoscope) inserted into the rectum. If the
doctor sees polyps or other abnormal tissue during the procedure , they can be
removed and further examined under a microscope. Studies suggest that
colonoscopy is a more effective screening method than barium enema.

,.

Several tests can help determine
whether you have colon cancer. Which
test is best for you depends on your
individual situation , for example,
whether you've had symptoms of colon
cancer or a family history of cancer or
polyps. M. D. Anderson Cancer Center
offers the fo llowing general colon cancer
screening recommendations (see Screening Tests for Colon Cancer) for men and
women beginning at age 50:
• An annual fecal occult blood test
and a flexible sigmoidoscopy and
digital rectal examination every
five years, or
• A colonoscopy and digital rectal
examination every 10 years, or
• A double-contrast barium enema
and digital rectal examination
every five to 10 years.
Now the good news: Colon can cer
can be cured if it is found early enough.
It can even be prevented if polyps are
fo und and removed before they have a
chance to tum into cancer. And removing polyps when they are small and
harmless is usually a simple procedure.
But h ere's the catch: You have to get
the test. You can 't just say "Great idea!"
and go on about your business. You h ave
to actually go see a doctor or other
health-care provider, find out wh at test
is recommended for you, and then do it.
When it's all over, you'll know that
you've done something really important
for yourself, your family, and everyon e
who depends on you. There will be
peace of mind for all involved. A nd
you'll h ave made someone who cares
about you very, very happy. •

For more information, contact
your physician or contact the
M . D. A nderson Information Line:
({) (800) 392-1611, Option 3,
within the United States, or
({) (713) 792-3245 in Houston
and outside the United States .
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Sexual Function and Prostate Cancer:
The Importance of Realistic Expectations

OncoLo
The University of Texas
M. 0. Anderson Cancer Center
President

Leslie R. Schover, Ph.D.
Professor, Department of
Behavioral Science
Many men choose
a treatment for
prostate cancer
ba ed on the
unreali tic expectation that it will pare
their exual function. When they do
end up with problems, the stigma of
being a "treatment failure" add yet another
barrier to their seeking medical help.
New treatment that are de igned to
eradicate pro tate cancer without compromising exual function have been highlighted in the professional literature and
the lay press, but they typically include only
younger, healthier patients who are treated
in academic medical centers. A consistently
less positive picture comes from published
findings in studies of unselected patients
treated in community settings, especially
when sexual function is assessed using
detailed, validated questionnaires.
The marketing of sildenafil has encouraged more men to get treatment for erectile
dysfunction, but it does not help many
prostate cancer urvivors. In our recent
follow-up study of men treated for localized
prostate cancer, only 16% of 549 men
who tried sildenafil found that it greatly
improved their ex lives, and 61 % had
stopped using it. More invasive treatments
such as penile injections or a penile prosthesi had much higher success rates.
8
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A narrow focu on erectil rigidity
overlook the role f the partn r in ucc
ful exual recovery after pro tat cane r.
In our survey, 66% of men
th ir
partner had a problem
ith
ex, mo t commonly a
urpri ingly, men who
ex were them elve m
What then can ph
men to re ume having exual i
after pro tate cancer tr atm nt?
• U e reali tic e timat
f th p re
of men wh e exual functi n i
after pro tate cane r tr atm nt.
• Empha ize that m n wh r tain r
regain normal erection are alm t
alway younger than 65 ( th y un r,
the better) and had normal er cti n
before treatment.
• Encourage men to try ph phodiestera e-5 (PDE-5) inhibitor , but with
the caveat that they work be t for men
who already have erection that are
close to normal and more in a ive
option may be needed.
• Include the partner in coun eling a
much as possible. Asse her exual
function and give referral when needed.
• If you do not have the time to educate
patients about the sexual impact of
treatment, delegate that ta k to one
of your treatment team member.
At least half of all pro tate cancer
survivor are concerned about taying
exually active. They and their partner
need your help and encouragement to
get their sex lives back on track.
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